Figure 1. Antiproliferative effects of BocNHO and CBI-indole₂ in prostate, breast and lung cancer cell lines. Prostate PC3-MM2 (A), breast EMT6 (B) and lung A549 (C) cells were treated with vehicle (▲), BocNHO (●) and CBI-indole₂ (■) for 24, 48 and 72 h. The BocNHO prodrug manifests equipotency compared with the parent molecule, CBI-indole₂, indicating free release of the active drug. Potency and efficacy increase in a dose- and time-dependent manner across all three cell lines. The structures of BocNHO and CBI-indole₂ are shown in (D).